Author
Listed:
- Di Wu
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University
Brigham and Women’s Hospital, Harvard Medical School)
- Di Hu
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University
Brigham and Women’s Hospital, Harvard Medical School)
- Hao Chen
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University
Boston Children’s Hospital)
- Guoming Shi
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University
Brigham and Women’s Hospital, Harvard Medical School)
- Irfete S. Fetahu
(Brigham and Women’s Hospital, Harvard Medical School)
- Feizhen Wu
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University
Brigham and Women’s Hospital, Harvard Medical School)
- Kimberlie Rabidou
(Brigham and Women’s Hospital, Harvard Medical School)
- Rui Fang
(Brigham and Women’s Hospital, Harvard Medical School)
- Li Tan
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University)
- Shuyun Xu
(Brigham and Women’s Hospital, Harvard Medical School)
- Hang Liu
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University)
- Christian Argueta
(Brigham and Women’s Hospital, Harvard Medical School)
- Lei Zhang
(Shanghai Medical School, Fudan University)
- Fei Mao
(Huashan Hospital, Fudan University)
- Guoquan Yan
(Shanghai Medical School, Fudan University)
- Jiajia Chen
(Shanghai Medical School, Fudan University)
- Zhaoru Dong
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University)
- Ruitu Lv
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University)
- Yufei Xu
(Brigham and Women’s Hospital, Harvard Medical School)
- Mei Wang
(Brigham and Women’s Hospital, Harvard Medical School)
- Yong Ye
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University)
- Shike Zhang
(Brigham and Women’s Hospital, Harvard Medical School)
- Danielle Duquette
(Brigham and Women’s Hospital, Harvard Medical School)
- Songmei Geng
(Brigham and Women’s Hospital, Harvard Medical School)
- Clark Yin
(Brigham and Women’s Hospital, Harvard Medical School)
- Christine Guo Lian
(Brigham and Women’s Hospital, Harvard Medical School)
- George F. Murphy
(Brigham and Women’s Hospital, Harvard Medical School)
- Gail K. Adler
(Brigham and Women’s Hospital, Harvard Medical School)
- Rajesh Garg
(Brigham and Women’s Hospital, Harvard Medical School)
- Lydia Lynch
(Brigham and Women’s Hospital, Harvard Medical School)
- Pengyuan Yang
(Shanghai Medical School, Fudan University)
- Yiming Li
(Huashan Hospital, Fudan University)
- Fei Lan
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University)
- Jia Fan
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University)
- Yang Shi
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University
Boston Children’s Hospital)
- Yujiang Geno Shi
(Institute of Clinical Science of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University
Brigham and Women’s Hospital, Harvard Medical School)
Abstract
Diabetes is a complex metabolic syndrome that is characterized by prolonged high blood glucose levels and frequently associated with life-threatening complications1,2. Epidemiological studies have suggested that diabetes is also linked to an increased risk of cancer3–5. High glucose levels may be a prevailing factor that contributes to the link between diabetes and cancer, but little is known about the molecular basis of this link and how the high glucose state may drive genetic and/or epigenetic alterations that result in a cancer phenotype. Here we show that hyperglycaemic conditions have an adverse effect on the DNA 5-hydroxymethylome. We identify the tumour suppressor TET2 as a substrate of the AMP-activated kinase (AMPK), which phosphorylates TET2 at serine 99, thereby stabilizing the tumour suppressor. Increased glucose levels impede AMPK-mediated phosphorylation at serine 99, which results in the destabilization of TET2 followed by dysregulation of both 5-hydroxymethylcytosine (5hmC) and the tumour suppressive function of TET2 in vitro and in vivo. Treatment with the anti-diabetic drug metformin protects AMPK-mediated phosphorylation of serine 99, thereby increasing TET2 stability and 5hmC levels. These findings define a novel ‘phospho-switch’ that regulates TET2 stability and a regulatory pathway that links glucose and AMPK to TET2 and 5hmC, which connects diabetes to cancer. Our data also unravel an epigenetic pathway by which metformin mediates tumour suppression. Thus, this study presents a new model for how a pernicious environment can directly reprogram the epigenome towards an oncogenic state, offering a potential strategy for cancer prevention and treatment.
Suggested Citation
Di Wu & Di Hu & Hao Chen & Guoming Shi & Irfete S. Fetahu & Feizhen Wu & Kimberlie Rabidou & Rui Fang & Li Tan & Shuyun Xu & Hang Liu & Christian Argueta & Lei Zhang & Fei Mao & Guoquan Yan & Jiajia C, 2018.
"Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer,"
Nature, Nature, vol. 559(7715), pages 637-641, July.
Handle:
RePEc:nat:nature:v:559:y:2018:i:7715:d:10.1038_s41586-018-0350-5
DOI: 10.1038/s41586-018-0350-5
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Yu-Jung Tseng & Yuki Kageyama & Rebecca L. Murdaugh & Ayumi Kitano & Jong Hwan Kim & Kevin A. Hoegenauer & Jonathan Tiessen & Mackenzie H. Smith & Hidetaka Uryu & Koichi Takahashi & James F. Martin & , 2024.
"Increased iron uptake by splenic hematopoietic stem cells promotes TET2-dependent erythroid regeneration,"
Nature Communications, Nature, vol. 15(1), pages 1-16, December.
- Jinzhu Zhang & Minghai Tang & Yujie Chen & Dan Ke & Jie Zhou & Xinyu Xu & Wenxian Yang & Jianxiong He & Haohao Dong & Yuquan Wei & James H. Naismith & Yi Lin & Xiaofeng Zhu & Wei Cheng, 2021.
"Catalytic flexibility of rice glycosyltransferase OsUGT91C1 for the production of palatable steviol glycosides,"
Nature Communications, Nature, vol. 12(1), pages 1-12, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:559:y:2018:i:7715:d:10.1038_s41586-018-0350-5. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.